C4 Therapeutics Inc
CCCC2.645USD
+0.035+1.34%
Market hours （ET）Quotes delayed by 15 min
187.81MMarket Cap
LossP/E TTM
More Details of C4 Therapeutics Inc Company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.
Company Info
Ticker SymbolCCCC
Company nameC4 Therapeutics Inc
IPO dateOct 02, 2020
CEOMr. Andrew J. Hirsch
Number of employees110
Security typeOrdinary Share
Fiscal year-endOct 02
Address490 Arsenal Way
CityWATERTOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02472
Phone16172310700
Websitehttps://c4therapeutics.com/
Ticker SymbolCCCC
IPO dateOct 02, 2020
CEOMr. Andrew J. Hirsch
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
165.12K
--
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
105.00K
+36.72%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
Ms. Jolie M. Siegel, J.D.
Ms. Jolie M. Siegel, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Courtney Solberg
Ms. Courtney Solberg
Senior Manager - Investor Relations
Senior Manager - Investor Relations
--
--
Dr. Laura Bessen, M.D.
Dr. Laura Bessen, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Kendra Adams
Ms. Kendra Adams
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
165.12K
--
Dr. Scott N. Boyle, Ph.D.
Dr. Scott N. Boyle, Ph.D.
Chief Business Officer
Chief Business Officer
107.81K
+90.58%
Dr. Paige Mahaney, Ph.D.
Dr. Paige Mahaney, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
105.00K
+36.72%
Mr. Utpal Koppikar
Mr. Utpal Koppikar
Independent Director
Independent Director
5.67K
--
Dr. Stephen Fawell, Ph.D.
Dr. Stephen Fawell, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donna Grogan, M.D.
Dr. Donna Grogan, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Wasatch Global Investors Inc
10.43%
Lynx1 Capital Advisors LLC
9.97%
Soleus Capital Management, L.P.
9.81%
OrbiMed Advisors, LLC
9.60%
Betta investment Hong Kong Ltd
6.85%
Other
53.34%
Shareholders
Shareholders
Proportion
Wasatch Global Investors Inc
10.43%
Lynx1 Capital Advisors LLC
9.97%
Soleus Capital Management, L.P.
9.81%
OrbiMed Advisors, LLC
9.60%
Betta investment Hong Kong Ltd
6.85%
Other
53.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor
22.79%
Investment Advisor/Hedge Fund
17.30%
Hedge Fund
15.75%
Private Equity
9.60%
Research Firm
7.79%
Corporation
6.85%
Individual Investor
3.28%
Venture Capital
0.15%
Pension Fund
0.13%
Other
16.36%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
314
71.31M
100.42%
-15.50M
2025Q1
338
73.30M
106.72%
-7.68M
2024Q4
337
73.17M
103.10%
-6.50M
2024Q3
332
72.91M
103.31%
-3.42M
2024Q2
325
69.49M
100.73%
-3.96M
2024Q1
329
66.54M
97.72%
+3.15M
2023Q4
324
51.20M
103.91%
-2.36M
2023Q3
320
38.85M
79.00%
-14.16M
2023Q2
326
38.30M
78.08%
-12.52M
2023Q1
331
41.73M
85.11%
-15.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wasatch Global Investors Inc
7.47M
10.52%
+748.92K
+11.14%
Apr 30, 2025
Lynx1 Capital Advisors LLC
7.10M
10%
+245.39K
+3.58%
Mar 31, 2025
Soleus Capital Management, L.P.
6.98M
9.83%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
6.83M
9.62%
+2.45M
+56.02%
Mar 31, 2025
Betta investment Hong Kong Ltd
4.87M
6.86%
-693.38K
-12.45%
Apr 22, 2025
Morgan Stanley & Co. LLC
2.45M
3.45%
-819.05K
-25.05%
Mar 31, 2025
The Vanguard Group, Inc.
3.37M
4.75%
+24.91K
+0.74%
Mar 31, 2025
BofA Global Research (US)
1.99M
2.8%
+313.18K
+18.67%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.72M
6.65%
-159.63K
-3.27%
Mar 31, 2025
Morgan Stanley Investment Management Inc. (US)
1.58M
2.22%
+1.02M
+182.53%
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Proshares Ultra Russell 2000
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
Invesco Dorsey Wright Healthcare Momentum ETF
0%
SPDR S&P Biotech ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0.01%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0%
SPDR S&P Biotech ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
